Summary#
The Prior Authorization Reform for Autoimmune and Blood Disorders Act is a bill that would amend the Employee Retirement Income Security Act (ERISA), the Public Health Service Act, and the Internal Revenue Code. Its stated goal is to require coverage of specified drugs and limit how often plans can require prior authorization (approval before coverage) for them. It has been introduced but is not law.
- Group health plans and health insurers would have to cover drugs and biological products indicated and prescribed for autoimmune diseases, hemophilia, or Von Willebrand disease.
- That coverage could not depend on whether the drug is dispensed by a pharmacy or given as part of another covered item or service.
- Plans and insurers generally could require prior authorization for a qualifying drug no more than once in any 12-month period for an enrolled person.
- The limit would not apply to drugs typically used for 12 months or less; opioids, benzodiazepines, barbiturates, or carisoprodol; or drugs subject to a federal risk evaluation and mitigation strategy.
- The changes would apply to plan years beginning on or after January 1, 2027. The bill creates no new office or program; it places duties on plans and insurers.
What it means for you#
- People enrolled in group health plans or individual health insurance: If a prescribed drug meets the bill’s definition, the plan or insurer would have to cover it. For drugs not in the exceptions, it generally could not require you to obtain prior authorization more than once in a 12-month period.
- People using an excepted drug: The bill would not limit how often prior authorization can be required for that drug.
- Health plans and insurers: They would have to meet the coverage and prior-authorization rules. The bill does not remove prior authorization altogether or say that every request must be approved.
- Patients generally: The bill does not set patient cost-sharing amounts, such as copayments, or change rules for drugs outside its definition.
Money#
No cost estimate is provided; no publicly available information is supplied about likely costs.
- The bill requires plans and insurers to cover qualifying drugs, but gives no estimate of how that requirement might affect spending, premiums, or other costs.
- It does not appropriate public money or set a new fee or fine.
What is unclear#
- The bill does not define “autoimmune disease,” “indicated,” or “typically used for a period of 12 months or less.”
- It does not set procedures, timelines, or appeal rules for coverage and prior-authorization decisions.
- It does not explain how the new rules would interact with existing coverage requirements. The parent Acts were not supplied, so current law and how much the bill would change it could not be verified.
- The text does not specify a new enforcement process or explain how violations would be handled.
- The bill does not give a start date within the 2027 plan year; it applies to plan years beginning on or after January 1, 2027.
Case for#
- A possible argument for the bill is that people using ongoing treatment could face fewer repeat prior-authorization requests for qualifying drugs.
- Requiring coverage whether a drug is dispensed by a pharmacy or provided as part of another covered service may address differences in how treatment is delivered.
- The exceptions preserve the ability to require more frequent authorization for certain drugs, including drugs typically used for a shorter period and drugs subject to a risk-management strategy.
Case against#
- The required coverage applies to any drug meeting the bill’s definition, but the bill does not define key terms such as “autoimmune disease.” That could leave uncertainty about which drugs qualify.
- Limiting repeat authorization may reduce a plan’s ability to reassess some ongoing prescriptions as often as it otherwise could. The bill does not explain what information plans may use for those decisions.
- The bill does not estimate whether the coverage requirement could increase plan costs or affect premiums.